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Summary
Background Tight and personalised control of inflammatory bowel disease in a traditional setting is challenging 
because of the disease complexity, high pressure on outpatient clinics, and rising incidence. We compared the effects 
of self-management with a telemedicine system, which was developed for all subtypes of inflammatory bowel disease, 
on health-care utilisation and patient-reported quality of care versus standard care.
Methods We did this pragmatic, randomised trial in two academic and two non-academic hospitals in the Netherlands. 
Outpatients aged 18–75 years with inflammatory bowel disease and without an ileoanal or ileorectal pouch 
anastomosis, who had internet access and Dutch proficiency, were randomly assigned (1:1) to care via a telemedicine 
system (myIBDcoach) that monitors and registers disease activity or standard care and followed up for 12 months. 
Randomisation was done with a computer-generated sequence and used the minimisation method. Participants, 
health-care providers, and staff who assessed outcome measures were not masked to treatment allocation. Primary 
outcomes were the number of outpatient visits and patient-reported quality of care (assessed by visual analogue scale 
score 0–10). Safety endpoints were the numbers of flares, corticosteroid courses, hospital admissions, emergency 
visits, and surgeries. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, 
number NCT02173002.
Findings Between Sept 9, 2014, and May 18, 2015, 909 patients were randomly assigned to telemedicine (n=465) or 
standard care (n=444). At 12 months, the mean number of outpatient visits to the gastroenterologist or nurse was 
significantly lower in the telemedicine group (1·55 [SD 1·50]) than in the standard care group (2·34 [1·64]; difference 
–0·79 [95% CI –0·98 to –0·59]; p<0·0001), as was the mean number of hospital admissions (0·05 [0·28] vs 0·10 [0·43]; 
difference –0·05 [–0·10 to 0·00]; p=0·046). At 12 months, both groups reported high mean patient-reported quality of 
care scores (8·16 [1·37] in the telemedicine group vs 8·27 [1·28] in the standard care group; difference 0·10 
[–0·13 to 0·32]; p=0·411). The mean numbers of flares, corticosteroid courses, emergency visits, and surgeries did 
not differ between groups.
Interpretation Telemedicine was safe and reduced outpatient visits and hospital admissions compared with standard 
care. This self-management tool might be useful for reorganising care of inflammatory bowel disease towards 
personalised and value-based health care.
Funding Maastricht University Medical Centre and Ferring. 
Introduction
Inflammatory bowel disease is a group of chronic, 
relapsing inflammatory disorders of the gut, with 
Crohn’s disease and ulcerative colitis being the main 
subtypes. The clinical presentations of these diseases 
vary widely among individuals, as shown by variations in 
disease location and behaviour, relapse frequency, extra-
intestinal manifestations, complications, and responses 
to treatment.1
Traditionally, management of inflammatory bowel 
disease consists of standard scheduled follow-up visits, 
with a frequency based on medical treatment, but 
independent of the occurrence of unpredictable flares.2,3 
Until recently, the primary treatment goal was induction 
and maintenance of clinical remission. However, disease 
management based on treating symptoms alone did not 
improve long-term outcomes, defined as the numbers of 
flares, courses of corticosteroid treatment, hospital 
admissions, complications, and surgeries.4,5 Therefore, 
recent guidelines advocate more stringent management, 
involving tight control of disease activity and early 
intervention in patients with intestinal inflammation.6 
Other interventions address aspects of inflammatory 
bowel disease that might influence disease activity, such 
as non-adherence to treatment, unfavourable nutritional 
status, smoking, and psychological factors.7–9 These 
interventions were shown to reduce the rates of disease 
relapse, health-care utilisation including hospital 
admission, and absence from work in subsets of 
patients.7–9 This approach, however, has not been 
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systematically implemented in routine care, because 
acquiring all the necessary information at the right 
moment for every individual patient remains a challenge. 
Furthermore, the heterogeneous nature of inflammatory 
bowel disease, combined with an absence of adequate 
markers for patient stratification, can lead to the 
underuse or overuse of resources.
Tight control of disease activity and personalised 
monitoring of all relevant health parameters during 
traditional visits put substantial pressure on patients’ 
time and the capacity of outpatient clinics. The incidence 
of inflammatory bowel disease is increasing and 
insurance companies, governments, and patient 
organisations increasingly demand registration of 
patient-reported outcome measures, patient-reported 
experience measures, and quality metrics.10–13 Therefore, 
reorganisation of health care for patients with 
inflammatory bowel disease is warranted.
Telemedicine systems, which have been used to 
manage chronic diseases, such as congestive heart failure 
and chronic obstructive pulmonary disease, have been 
shown to improve quality of care and could help optimise 
the use of available resources.14,15 Telemedicine allows for 
the strict and instantaneous follow-up of health 
parameters and timely, personalised interventions. 
Moreover, these systems can provide tailored information 
based on each patient’s needs.
At present, few telemedicine systems that can improve 
disease outcomes, increase patients’ empowerment, and 
reduce health-care utilisation are available for patients 
with inflammatory bowel disease.7,16–21 However, these 
tools were developed for patients with specific subtypes 
of inflammatory bowel disease, consisting of those with 
mild-to-moderate disease activity. Studies provide 
inconsistent results on the effects of these telemedicine 
systems on disease outcomes, compromising their use in 
real-world settings.
We therefore developed a telemedicine system 
(myIBDcoach) that monitors and registers disease 
activity in patients with all subtypes of inflammatory 
bowel disease. This system, which can be used in both 
academic and non-academic hospitals, also monitors 
other disease-related parameters, including patient-
reported outcome measures and quality metrics. This 
Research in context
Evidence before this study
We searched PubMed and MEDLINE for randomised controlled 
trials of telemedicine in inflammatory bowel diseases published 
up to Dec 20, 2016, with the terms “telemedicine”, “eHealth”, 
“mHealth”, “inflammatory bowel disease”, “randomised 
controlled trial”, and “adults”. This search retrieved two 
randomised studies, both of which were in patients with 
ulcerative colitis. The first trial compared self-testing of disease 
activity and weight measurements versus standard care in 
47 patients; no differences were seen between groups in disease 
activity, medication adherence, and quality of life. The second 
trial included 333 patients with mild-to-moderate disease 
treated with mesalazine and found that tight disease monitoring 
and personalised treatment strategies resulted in an 
improvement of patient empowerment, quality of life, and 
medication adherence, and a reduction in outpatient visits and 
relapse duration compared with usual care. Because both studies 
reported data on the effects of telemedicine for a specific 
subgroup, no reliable conclusion could be drawn on the 
effectiveness of telemedicine for the entire population of 
patients with inflammatory bowel disease or on which subtypes 
of patients are likely to benefit most. This shortcoming 
compromises the use of telemedicine systems in real-world 
settings.
Added value of this study
Our study includes data on the effects of telemedicine in 
patients with all subtypes of inflammatory bowel disease, 
irrespective of phenotype, disease course, or medication use. 
Telemonitoring in combination with patient-tailored 
information, a personal care plan, easy, accessible contact with 
the inflammatory bowel disease nurse, and registration of 
patient-reported outcome measures resulted in a reduction in 
health-care utilisation and hospital admissions. Furthermore, 
the telemedicine system myIBDcoach improved medication 
adherence and patients reported similar scores for quality of 
care compared with the standard care group. These results were 
consistent across different patient subtypes. Our findings 
accord with those in other chronic relapsing-remitting diseases 
and suggest that tight disease monitoring and early 
intervention in case of a relapse can prevent admission to 
hospital. Trials with a longer follow-up period are required to 
determine whether telemedicine can change the natural disease 
course of chronic diseases in the long term.
Implications of all the available evidence
Routine follow-up of patients with inflammatory bowel disease, 
traditionally consisting of prescheduled visits that are unlikely to 
correspond with its unpredictable clinical course, puts increasing 
pressure on outpatient clinics, compromising accessibility and 
quality of care. Implementation of telemedicine in inflammatory 
bowel disease care bridges the gap between the health-care 
workers’ requests for tight disease monitoring and continuity of 
care in an overburdened outpatient setting and patients’ 
demands for more involvement in disease management. 
Telemedicine is safe, highly accepted by patients and health-care 
workers, and can be used to reorganise care for patients with all 
subtypes of inflammatory bowel disease. In our clinic, 
myIBDcoach will be used in a value-based health-care initiative. 
Furthermore, patients in remission or with mild disease will be 
monitored and guided with telemedicine supervised by a 
specialised nurse to guarantee adequate access to the 
gastroenterologists’ outpatient clinic for those patients with 
complex disease or in need of urgent action.
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information is displayed in a manner understood by the 
user and his or her health-care providers. Integrated care 
and patient empowerment are promoted by a 
communication function and a wide range of web-based 
learning methods. A pilot study showed that integration 
of myIBDcoach into routine care was feasible and well 
accepted by patients as well as health-care providers.22 We 
postulated that use of this telemedicine system in routine 
care could reduce health-care utilisation, while ensuring 
tight disease monitoring and high patient-experienced 
quality of care. We did a pragmatic, multicentre, 
randomised controlled trial to investigate the effect of 
care with this telemedicine system on outpatient visits, 
patient-reported quality of care, and disease outcomes, 
and compared these effects with those of standard care.
Methods
Study design and participants
This pragmatic randomised trial was done at four 
hospitals in the Netherlands: two academic hospitals 
(Maastricht University Medical Centre and Leiden 
University Medical Centre), and two large, non-academic, 
regional hospitals (Zuyderland Medical Centre, Sittard, 
and St Antonius Hospital, Nieuwegein). Each 
participating hospital serves 1500–2000 patients with 
inflammatory bowel disease, had one or two dedicated 
nurses or nurse specialists, and had an e-mail and 
telephone consultation structure for patients with 
inflammatory bowel disease to contact the hospital. 
Furthermore, each hospital provided patients with the 
opportunity to consult by telephone with a nurse (at 
least) three times per week at fixed timepoints. Patients 
were enrolled at the outpatient clinic of the four 
participating hospitals. All consecutive patients between 
18 and 75 years of age, fulfilling the international 
diagnostic criteria for inflammatory bowel disease,23 were 
eligible for inclusion. Exclusion criteria were an inability 
to read or understand the informed consent form, and 
lack of internet access by computer, tablet, or smartphone. 
Additionally, patients with a hospital admission within 
2 weeks before inclusion were excluded for ethical 
reasons, because these patients were deemed unable to 
make an informed decision for participation. Patients 
with an ileoanal pouch or ileorectal anastomosis were 
also excluded. The study was approved by the medical 
research ethics committee of the Maastricht University 
Medical Centre. This approval was applicable to all 
participating centres. The study protocol is available 
online in Dutch.
Randomisation and masking
After signing the informed consent form, patients were 
randomly assigned (1:1) to care via the telemedicine 
system (intervention) or standard care (control). 
Randomisation was done with ALEA Screening and 
Enrolment Application Software using the minimisation 
method, stratified for medical centre, subtypes of 
inflammatory bowel disease (Crohn’s disease or 
ulcerative colitis), and treatment (no medication or 
mesalazine; immunosuppressive drugs; or biological 
therapy). Participants, health-care providers, and staff 
who assessed outcome measures were not masked to 
treatment allocation.
Procedures
The details of the telemedicine system myIBDcoach have 
been described elsewhere.22 MyIBDcoach is a secured 
webpage with an HTML application for tablet or 
smartphone (figure 1). The system includes monthly 
monitoring modules, which contain questions regarding 
disease activity, medication use, treatment adherence, 
treatment satisfaction, and side-effects, including 
infections. The system also includes questions on factors 
affecting disease (including nutritional status, smoking, 
stress, life events, anxiety and depression, social support, 
physical exercise, and self-management skills), and 
patient-reported outcome measures on quality of life and 
work productivity. In monitoring disease activity, 
myIBDcoach uses the newly developed Monitor IBD At 
Home (MIAH) questionnaire, a symptom-based patient-
reported outcome measure validated relative to endoscopy. 
This questionnaire does not require laboratory tests or 
physical examination, and shows good diagnostic accuracy 
in screening for patients requiring further assessment of 
disease activity with biochemical markers, imaging, or 
endoscopy.24 When the disease was in remission, defined 
as three consecutive low monthly MIAH scores, patients 
were allowed to complete the monitoring module once 
every 3 months. Furthermore, the system includes 
intensified monitoring modules (weekly in case of flare), 
outpatient visit modules (to prepare for an outpatient 
visit), e-learning modules, a personal care plan, and an 
administrator page used by the health-care provider (ie, 
gastroenterologist or nurse). When parameters recorded 
by the monitoring modules exceeded predefined 
thresholds, the safety and continuity of care were ensured 
by the creation of alerts (red flags) on the administrator 
page of each local hospital. In all participating centres, the 
administrator page was checked at least twice daily apart 
from weekend days. If an alert was received, a health-care 
provider on the local team contacted the patient for further 
assessment within two working days. Visits to the 
outpatient clinic were based on the nature and severity of 
the clinical complaints. At any time, patients were able to 
communicate easily with their health-care provider by 
sending a message to the health-care providers’ 
administration office.
Patients assigned to the intervention group received 
instructions, a username, and a password for the 
telemedicine system. Participants used the system for 
12 months and were instructed to plan at least one routine 
outpatient visit per year. Additional follow-up visits were 
scheduled on the basis of alarm symptoms recognised by 
the telemedicine system or at the requests of individual 
For the myIBDcoach webpage 
see http://www.mijnibdcoach.nl
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patients. Patients in the standard care group continued 
their routine follow-up visits following the local protocol, 
with an opportunity to schedule an extra visit if symptoms 
relapsed. At baseline and after 12 months, all participants 
received a paper questionnaire regarding perceived 
quality of care, medication adherence, quality of life, 
self-efficacy, disease-related and medication-related 
knowledge, and smoking behaviour.
Outcomes
The primary outcomes were the number of outpatient 
visits and patient-reported quality of care. The number of 
outpatient visits and telephone consultations with 
gastroenterologists and nurses during the 12 month period 
were retrieved from patients’ electronic medical records. 
Because validated patient-reported quality of care 
questionnaires have insufficient content validity for 
telemedicine interventions, patient-reported quality of care 
was measured with seven relevant domains derived from 
different questionnaires. These domains included visual 
analogue scale (VAS) scores (0–10; higher score indicates 
higher quality) on patient satisfaction with health care, 
patients’ experiences contacting their health-care providers, 
and the extent to which health care meets patients’ 
expectations. Questions were also included on the health-
care workers’ timeliness of response to questions and 
symptoms, health-care workers’ fulfilment of agreements 
and attentiveness to acute situations, and hospital 
accessibility in case of symptoms. A mean score of 8 out of 
10 or higher was predefined as perceived high quality.
Secondary outcomes were adherence to treatment, 
quality of life, self-efficacy, disease-related and 
medication-related knowledge, smoking behaviour, and 
disease outcomes. Disease outcomes were the numbers 
of flares and inflammatory bowel disease-related 
hospital admissions, emergency visits, surgeries, and 
corticosteroid use during the 12 months of follow-up. 
Flares were defined as clinical symptoms indicative of 
disease activity with, as a rule, concomitant calprotectin 
of more than 250 µg/g in the stool or active disease 
determined by endoscopy, MRI, or CT. In daily practice, 
in case of clinically severe symptoms suggestive for 
disease activity, the treating physician occasionally 
judged these symptoms to be evident enough to adjust 
therapy. Therefore, to capture all clinical flares, clinical 
episodes were defined as flares if symptoms suggestive 
of disease activity resulted in a dose escalation or 
initiation of a new drug to induce remission. Medication 
adherence was measured with the eight-item Morisky 
Medication Adherence Scale,25 with scores below 6 
defined as low adherence, scores between 6 and 8 
defined as moderate adherence, and a score of 8 defined 
as high adherence. Quality of life was measured with 
the Short Inflammatory Bowel Disease Questionnaire 
(SIBDQ), a ten-item questionnaire that covers four 
domains: bowel symptoms, systemic symptoms, 
emotional health, and social functions.26 Overall scores 
on the SIBDQ range from 10 to 70, with a lower score 
indicating lower quality of life. Self-efficacy, defined as 
the perception of one’s ability to engage in skills 
required to master a new challenge despite obstacles, 
was measured with the 29-item inflammatory bowel 
disease self-efficacy scale (IBD-SES).27 Questions are 
grouped into four domains: managing stress and 
emotions, managing medical care, managing 
symptoms and disease, and maintaining remission. 
Telemedicine
Patient Administration office, 
inflammatory bowel disease clinic
Monitoring module 
Intensified monitoring module 




Figure 1: Overview of the elements of the telemedicine system myIBDcoach
(1) Modules containing different questionnaires: standard monitoring (every month, or every 3 months when the disease is in remission), intensified monitoring 
(weekly in case of a flare), and outpatient visit monitoring (to prepare an outpatient visit). When parameters recorded by the monitoring modules exceed predefined 
thresholds, alerts (red flags) are created on the administrator page of the inflammatory bowel disease clinic. (2) Personal care plan: summary and visualisation of 
health parameters, patient-reported outcome measures, and quality metrics. (3) e-learning modules: interactive patient-tailored information on topics such as 
medications, adherence to medication, smoking cessation, (mal)nutrition, methods to prevent or reduce symptoms (self-management), fatigue, work productivity, 
anxiety, and depression. (4) Communication: secure message connection between patient and health-care providers’ administrator page. Figure adapted from 
de Jong M, van der Meulen-de Jong A, Romberg-Camps M, et al. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. 
Inflamm Bowel Dis 2017; 23: 485–93. http://journals.lww.com/ibdjournal/Abstract/2017/04000/Development_and_Feasibility_Study_of_a.1.aspx.
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Overall scores on the IBD-SES range from 29 to 290, 
with higher scores indicating higher self-efficacy and 
thus better self-management and greater patient 
empowerment. Knowledge of inflammatory bowel 
disease and medication were both assessed by a 
VAS score (0–10; higher score indicates better 
knowledge), whereas smoking behaviour was assessed 
with a categorical question (non-smoker, active-smoker, 
or ex-smoker).
Statistical analysis
A sample size of 435 patients per group was estimated as 
sufficient to detect a difference of one outpatient visit per 
year (SD 2·4) and 0·5 difference in mean quality of care 
on a VAS scale (SD 1·4), with 80% power, a 5% significance 
level, and assuming a 10% dropout rate. Data were 
analysed on an intention-to-treat basis. Between-group 
differences in the number of outpatient consultations 
and disease outcomes were analysed by multivariable 
linear regression adjusted for the stratification criteria 
(medical centre [ four centres], subtypes of inflammatory 
bowel disease [Crohn’s disease or ulcerative colitis], 
and treatment [no medication or mesalazine; 
immunosuppressive drugs; or biological therapy]) and 
for age (numerical), sex (male or female), disease 
duration (numerical), disease activity at baseline 
(remission or active), smoking (non-smoker, active-
smoker, or ex-smoker), and educational level (five levels). 
Because the normality assumption might be violated 
because of outliers, its effect on the results was checked 
by comparing the obtained confidence intervals with 
those after bootstrapping. The multiple imputation 
method was used for missing outcomes and covariates, 
in which 20 complete datasets were created using all 
other variables in the aforementioned analysis model 
(outcome and covariate, including study group) to 
impute the missing data. Linear mixed model analyses 
were used to assess differences in patient-reported 
outcomes at baseline and 12 months; outcomes analysed 
included quality of care, quality of life, medication 
adherence, self-efficacy, and disease-related and 
medication-related knowledge. An unstructured 
covariance structure for the two repeated measures was 
considered and a likelihood based approach was used for 
missing outcome variables. Results were corrected for 
stratification criteria and for age, sex, disease duration, 
disease activity at baseline, smoking, and educational 
level. The consistency of the intervention effect was 
assessed across subtypes of sex, age (18–30, 31–50, and 
>50 years), subtypes of inflammatory bowel disease 
(Crohn’s disease and ulcerative colitis), setting (academic 
and non-academic), medication (no medication or 
mesalazine; immunosuppressive drugs; and biological 
therapy), and disease duration (0–5, 6–10, and >10 years), 
by post-hoc analyses where interaction terms of these 
variables with group (intervention and control) were 
added separately to the aforementioned linear regression 
and linear mixed models. The adjusted intervention 
effects that were estimated with these models are 
reported together with their 95% CI and p values. Logistic 
regression analysis was used to assess the intervention 
effect on smoking behaviour (active vs non-active [ex-
smoker or non-smoker]) and was corrected for baseline 
smoking behaviour (active vs non-active) and educational 
level. A two-sided p≤0·05 was defined as statistically 
significant. All statistical analyses were done with SPSS 
version 22.0. This trial is registered with ClinicalTrials.
gov, number NCT02173002.
Role of the funding source
The funding source had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Figure 2: Trial profile
We sent out 3000 invitation letters to patients who had a scheduled outpatient visit. Additionally, a small, but 
unknown, number of letters were given directly to the patients during outpatient visits, as some patients 
rescheduled their visit or had not received the invitation letter.
~3000 patients assessed for eligibility
909 randomly assigned
465 allocated to telemedicine
456 started telemedicine 444 started routine follow-up
438 completed 12 month follow-up 443 completed 12 month follow-up
465 included in analysis (intention-to-treat
 population)
444 included in analysis (intention-to-treat
 population)
444 allocated to standard care
~2091 excluded
 17% did not meet inclusion criteria
 12% declined to participate
 41% did not return the invitation letter
9 never registered with telemedicine 
 system
18 lost to follow-up
 4 refused participation
 3 moved to other region
 2 because of psychiatric illness
 1 because of critically ill husband
 2 preferred outpatient visits
 1 deceased
 1 felt unconfident with 
  telemedicine system
 4 unknown
1 lost to follow-up
 1 refused participation
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Results
Between Sept 9, 2014, and May 18, 2015, about 
3000 outpatients with inflammatory bowel disease were 
asked to participate in this study, of whom 17% did not 
meet the inclusion criteria, 41% did not return the 
invitation letter, and 12% were not interested, providing 
reasons such as “too busy”, “participating in other studies”, 
“not now”, “too much confrontation with the disease”, and 
“impersonality of telemedicine” (figure 2). 909 eligible 
patients provided written informed consent and were 
randomly assigned, 465 to the telemedicine group and 
444 to the standard care group. Neither protocol deviations 
nor adverse events related to use of the telemedicine 
intervention occurred. The baseline characteristics of the 
two study groups were similar and were representative of 
the general inflammatory bowel disease population in 
demographic characteristics and disease activity (table 1).28 
At the end of the 12 month study period, 438 (94%) patients 
in the telemedicine group continued to use the 
telemedicine system and 443 (99·8%) in the standard care 
group continued their routine follow-up visits in the same 
hospital (figure 2). At baseline, 382 (82%) patients in the 
telemedicine group and 369 (83%) in the standard care 
group completed the paper questionnaires about perceived 
quality of care, medication adherence, quality of life, self-
efficacy, disease-related and medication-related knowledge, 
and smoking behaviour. At 12 months, these questionnaires 
were completed by 340 (73%) patients in the telemedicine 
group and 331 (75%) patients in the standard care group. 
All randomised patients were included in the analyses 
(intention-to-treat population). One patient in the 
telemedicine group died because of mucinous colorectal 
cancer, which was deemed to be unrelated to the study 
intervention.
At 12 months, the mean number of outpatient visits to 
the gastroenterologist was significantly lower in the 
telemedicine group than in the standard care group 
(1·26 [SD 1·18] in the telemedicine group vs 1·98 [1·19] in 
the standard care group; estimated intervention effect 
–0·72 [95% CI –0·87 to –0·56]; p<0·0001; table 2). 
Outpatient visits to the nurse, however, did not differ 
significantly between groups (table 2). The total number 
of outpatient visits (gastroenterologist or nurse) was 
significantly lower in the telemedicine group than in the 
standard care group (1·55 [1·50] in the telemedicine 
group vs 2·34 [1·64] in the standard care group; estimated 
intervention effect –0·79 [–0·98 to –0·59]; p<0·0001). The 
mean number of telephone consultations with the 
gastroenterologist was also significantly lower in the 
telemedicine group than in the standard care group, but 
the mean number of telephone consultations with the 
nurse did not differ significantly (table 2). These results 
were largely consistent across patients with Crohn’s 
disease and ulcerative colitis, those treated in academic 
and non-academic settings, men and women, all age 
categories, all medication categories, and all disease 
duration categories (appendix pp 1–2). However, for 
patients in academic settings, the mean number of 
outpatient visits to the nurse was lower in the telemedicine 






Maastricht University Medical Centre 133 (29%) 131 (30%)
Leiden University Medical Centre 144 (31%) 152 (34%)
Zuyderland Medical Centre, Sittard 117 (25%) 102 (23%)
St Antonius Hospital, Nieuwegein 71 (15%) 59 (13%)
Sex
Men 194 (42%) 180 (41%)
Women 271 (58%) 264 (59%)
Age at diagnosis (years) 30·7 (13·5) 30·4 (13·6)
Age at inclusion (years) 44·0 (14·1) 44·1 (14·2)
Disease duration (years) 12·8 (10·4) 13·1 (10·8)
Phenotype
Crohn’s disease* 282 (61%) 262 (59%)
Ileal 87 (31%) 68 (26%)
Colonic 67 (24%) 63 (24%)
Ileocolonic 128 (45%) 131 (50%)
Upper gastrointestinal modifier 34 (12%) 26 (10%)
Non-penetrating, non-stricturing, B1 169 (60%) 152 (58%)
Stricturing, B2 76 (27%) 70 (27%)
Penetrating, B3 37 (13%) 40 (15%)
Perianal disease modifier 67 (24%) 62 (24%)
Ulcerative colitis† 183 (39%) 182 (41%)
Proctitis, E1 26 (14%) 27 (15%)
Left-sided, E2 81 (44%) 70 (38%)
Pancolitis, E3 76 (41%) 85 (47%)
Treatment
No medication or mesalazine 173 (37%) 147 (33%)
Immunosuppressive drugs 122 (26%) 131 (30%)
Biological therapy 170 (37%) 166 (37%)
Baseline disease activity
Remission 394 (85%) 380 (86%)
Active disease 71 (15%) 64 (14%)
Smoking
Non-smoker 157 (41%) 159 (43%)
Active smoker 65 (17%) 50 (14%)
Ex-smoker 157 (41%) 158 (43%)
Missing data 86 (18%) 77 (17%)
Education
University 54 (14%) 49 (13%)
Higher vocational education 103 (27%) 98 (27%)
Intermediate vocational education 160 (42%) 157 (43%)
Secondary education 56 (15%) 55 (15%)
Primary education 6 (2%) 8 (2%)
Missing data 86 (18%) 77 (17%)
Data are n (%) or mean (SD). *The number of patients with Crohn’s disease is 
used as the denominator for the percentages of each subtype of Crohn’s 
disease. †The number of patients with ulcerative colitis is used as the 
denominator for the percentages of each subtype of ulcerative colitis. 
Table 1: Baseline characteristics
See Online for appendix
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Patients in the telemedicine and standard care groups 
reported similar and high scores for quality of care at 
12 months (8·16 [SD 1·37] vs 8·27 [1·28], respectively; 
estimated intervention effect 0·10 [95% CI –0·13 to 0·32]; 
p=0·411; table 3). Results were similar in patients with 
Crohn’s disease and ulcerative colitis, those treated in 
academic and non-academic settings, men and women, 
and in all age and disease duration categories. Patients in 
the telemedicine group using biological therapies 
reported lower scores for quality of care than did patients 
in the standard care group (p=0·037; appendix pp 3–4).
Over the 12 month follow-up period, the mean 
numbers of flares, courses of corticosteroid treatment, 
emergency visits, and inflammatory bowel disease-
related surgeries did not differ significantly between the 
two groups (table 4). The mean number of hospital 
admissions was significantly lower in the telemedicine 
group than in the standard care group (16 unique 
patients admitted to hospital in the telemedicine group 
vs 29 in the standard care group; estimated intervention 
effect –0·05 [95% CI –0·10 to 0·00]; p=0·046). Reasons 
for admission to hospital included exacerbation of 
disease (six patients in the telemedicine group vs eight 
in the standard care group), surgery (eight vs ten), 
complications of the disease (ie, intestinal obstruction, 
active perianal disease, or ostomy dysfunction; six vs 14), 
medication side-effects (one vs six), and abdominal pain 
without evidence for active disease (none vs five). 
Analyses per subtype showed no significant differences 
between groups in numbers of flares, courses of 
corticosteroid treatment, emergency visits, and 
inflammatory bowel disease-related surgeries (appendix 
pp 5–6). However, patients in the telemedicine group 
with Crohn’s disease (estimated intervention effect 
–0·09 [95% CI –0·17 to –0·02]; p=0·012), or using 
biological therapies (–0·12 [–0·22 to –0·02]; p=0·025), 
or with a disease duration of more than 10 years (–0·08 
[–0·17 to 0·00]; p=0·045) were less often admitted to the 
hospital than their respective controls.
Adherence to medication at the end of the trial was 
significantly higher in the telemedicine group than in 
the standard care group (table 3). Both groups reported 
normal values for quality of life and high scores for self-
efficacy and disease-related and medication-related 
knowledge, with no significant differences between 
groups (table 3). Smoking behaviour at the end of the 
study period did not differ between groups (odds ratio 
0·81 [95% CI 0·33–1·96]; p=0·633; appendix p 7).
Discussion
This pragmatic, randomised controlled trial compared 
a telemedicine system versus standard outpatient care 
for patients with inflammatory bowel disease, 
irrespective of disease course or treatment. Our 
findings showed that use of the telemedicine system 
resulted in a reduction in outpatient visits, telephone 
consultations, and admissions to hospital, and 
increased adherence to medication. Additionally, the 
telemedicine system was safe and patient-reported 
quality of health care remained high.
Ameliorating quality of care for chronic diseases has 
been defined as improving long-term disease outcomes, 
creating a healthier population, and reducing health-care 
costs.12,29 Our results showed that the use of a telemedicine 
system reduced the number of outpatient visits, while 









Gastroenterologist 1·26 (1·18) 1·98 (1·19) –0·72 (–0·87 to –0·56) <0·0001
Nurse 0·29 (0·68) 0·36 (0·84) –0·07 (–0·17 to 0·03) 0·173
Total 1·55 (1·50) 2·34 (1·64) –0·79 (–0·98 to –0·59) <0·0001
Telephone consultations
Gastroenterologist 0·58 (0·98) 0·84 (1·11) –0·26 (–0·40 to –0·12) 0·0003 
Nurse 0·70 (1·59) 0·74 (1·90) –0·08 (–0·30 to 0·13) 0·448
Total 1·28 (2·06) 1·57 (2·44) –0·34 (–0·63 to –0·06) 0·018
Data are mean (SD) unless otherwise stated. *Adjusted for centre, treatment, subtypes of inflammatory bowel disease, 
age, sex, disease duration, disease activity at baseline, smoking, and educational level. Bootstrap CIs were similar to 
those presented here. The estimated intervention effect, 95% CI, and p value were obtained after multiple imputation. 
Table 2: Health-care utilisation




Number Mean score (SD) Number Mean score (SD)
Quality of care
Baseline 382 8·25 (1·24) 369 8·26 (1·05) ·· ··
12 months 340 8·16 (1·37) 331 8·27 (1·28) 0·10 (–0·13 to 0·32) 0·411
Medication adherence
Baseline 382 6·52 (1·76) 369 6·67 (1·70) ·· ··
12 months 340 7·01 (1·40) 331 6·77 (1·61) 0·46 (0·22 to 0·70) 0·0002
Quality of life
Baseline 382 53·34 (10·29) 369 53·42 (9·95) ·· ··
12 months 340 54·44 (9·05) 331 53·71 (9·87) 1·22 (–0·04 to 2·49) 0·057
Self-efficacy
Baseline 382 224·16 (64·04) 369 222·14 (36·88) ·· ··
12 months 340 223·35 (32·11) 331 220·28 (35·08) 2·45 (–6·05 to 10·94) 0·572
Knowledge of inflammatory bowel disease
Baseline 382 7·66 (1·30) 369 7·57 (1·36) ·· ··
12 months 340 8·17 (1·16) 331 7·84 (1·47) 0·20 (–0·19 to 0·41) 0·074
Knowledge of medication
Baseline 382 7·34 (1·51) 369 7·29 (1·44) ·· ··
12 months 340 7·75 (1·58) 331 7·58 (1·51) 0·14 (–0·09 to 0·37) 0·235
Quality of care was assessed by visual analogue scale, medication adherence by the eight-item Morisky Medication 
Adherence Scale,25 quality of life by the Short Inflammatory Bowel Disease Questionnaire,26 and self-efficacy by the 
inflammatory bowel disease self-efficacy scale.27 *Adjusted for centre, treatment, subtypes of inflammatory bowel 
disease, age, sex, disease duration, disease activity at baseline, smoking, educational level, and baseline 
patient-reported values. Bootstrap CIs were similar to those presented here. The estimated intervention effect, 95% CI, 
and p value were obtained from linear mixed models based on the likelihood approach for missing outcome data. 
Table 3: Patient-reported outcomes
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monitoring with the telemedicine system was safe, 
because there were no significant differences between 
groups in numbers of flares, corticosteroid courses, 
emergency visits, and surgeries. Moreover, use of the 
telemedicine system resulted in fewer hospital 
admissions. These results are in line with the improved 
care and monitoring with telemedicine in other 
(relapsing-remitting) chronic diseases, such as chronic 
obstructive pulmonary disease and heart failure.14,15 
However, those studies were done in fairly small and 
specific patient subgroups, with differences in follow-up 
times and outcome measures, resulting in inconsistent 
results. This inconsistency complicates the ability to 
draw firm conclusions on the effectiveness of 
telemedicine in larger real-world populations.
To our knowledge, myIBDcoach is the first telemedicine 
tool for all subtypes of inflammatory bowel disease, 
irrespective of phenotype, setting, medical treatment, or 
disease severity. Two previous randomised controlled trials 
assessed the effect of telemedicine on the management of 
subtypes of inflammatory bowel disease with mild 
disease.19,20 One trial, in 47 patients with ulcerative colitis, 
compared self-testing of disease activity by questionnaires 
and weight measurements with standard care, but found 
no differences between groups in disease outcomes.20 The 
other trial, in 333 patients with mild-to-moderate ulcerative 
colitis who were being treated with mesalazine, showed 
that tight monitoring of disease activity and personalised 
treatment strategies reduced outpatient visits compared 
with usual care.19 By contrast with our findings, disease 
activity, relapse frequency, and rates of hospital admission 
and surgery did not differ in the two groups. However, 
active self-management shortened relapse duration. As in 
our study, telemedicine improved adherence to treatment, 
but we did not find differences in quality of life, self-
efficacy, and disease-related and medication-related 
knowledge, which might have been caused by the high 
baseline scores on these questionnaires in both the 
telemedicine and standard care groups.26,27 Our study was 
done in four centres with well organised and accessible 
outpatient clinics with dedicated nurses and an e-mail and 
telephone consultation structure. As a consequence, rates 
of outpatient visits were relatively low compared with other 
European clinics,30 suggesting that the effect of the 
telemedicine system on the reduction of outpatient visits 
might be larger in other clinics.
In addition to disease activity, myIBDcoach also 
monitors factors that affect disease outcomes, including 
adherence to treatment, psychosocial factors, smoking, 
and nutrition. Awareness of these factors and 
development of standard intervention procedures and 
educational programmes can further improve the 
long-term outcome of patients with inflammatory bowel 
disease. For example, improved medication adherence 
has been found to improve long-term disease outcomes.7,8 
The telemedicine system offers interactive e-learning 
modules on various subjects, allowing patients to review 
modules when they or their health-care providers 
consider it desirable. The system also registers patient-
reported outcome measures on quality of life and work 
productivity, and quality metrics for value-based health 
care following the International Consortium for Health 
Outcomes Measurement recommendations. These 
findings can immediately be visualised and reported to 
both individual users and their health-care providers in a 
personal care plan. Hospitals with value-based health-
care programmes could use telemedicine systems to 
measure patient-reported outcome measures and 
patient-reported experience measures.10 Furthermore, 
systematic registration of quality metrics and aggregation 
of these metrics from different practices might improve 
quality of care and reduce practice variability.11,31
The main strength of our study was its randomised and 
pragmatic design. An unselected heterogeneous group of 
patients, clinicians, and clinical practices were included 
to maximise the applicability of these results to everyday 
practice. A potential weakness of the study design was 
that neither patients nor clinicians were masked to group 
assignments. We discussed giving all patients the 
telemedicine system while only monitoring patients in 
the intervention group. However, we felt that it was not 
ethical to ask the control group to use the telemedicine 
system without monitoring possibly relevant information 
resulting from red flags, nor to instruct those patients to 
plan follow-up visits only when necessary rather than 
traditionally booked appointments. The fairly short 
follow-up period can also be considered a limitation of 
the study. Intervention trials with 12 month follow-up 
are, however, regarded sufficient for maintenance drug 
therapy for registration purposes. Nevertheless, clinicians 
and patients require time to adapt to an altered clinical 
workflow. Interventions based on aberrant patient-
reported outcome measure values require new 
procedures and protocols. Trials with longer follow-up 
periods are required to determine whether the 
telemedicine system can control costs and improve long-
term disease outcomes.
Although telemedicine shows many benefits in 
managing patients with chronic diseases, few “tele-








Flares 0·19 (0·42) 0·19 (0·44) –0·01 (–0·06 to 0·05) 0·819
Corticosteroid courses 0·10 (0·33) 0·12 (0·37) –0·02 (–0·07 to 0·02) 0·322
Hospital admissions 0·05 (0·28) 0·10 (0·43) –0·05 (–0·10 to 0·00) 0·046
Emergency visits 0·07 (0·35) 0·10 (0·54) –0·03 (–0·09 to 0·03) 0·366
Inflammatory bowel 
disease-related surgeries
0·03 (0·16) 0·03 (0·16) 0·00 (–0·02 to 0·02) 0·786
Data are mean (SD) unless otherwise stated. *Adjusted for centre, treatment, subtypes of inflammatory bowel disease, 
age, sex, disease duration, disease activity at baseline, smoking, and educational level. Bootstrap CIs were similar to 
those presented here. The estimated intervention effect, 95% CI, and p value were obtained after multiple imputation.
Table 4: Disease outcomes
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Among the reasons are the absence of a framework for 
the development, evaluation, and implementation of 
eHealth interventions;18 a disconnect between users and 
developers of health IT systems;32 the development of 
telemedicine programmes aimed at specific subgroups 
of patients with regard to treatment regimen, disease 
severity, or health-care setting;7,19–21 and financial hurdles 
such as reimbursement of telemedicine consultations by 
insurance companies. To overcome these barriers, 
myIBDcoach was developed and pilot-tested with a 
structured iterative process and through close 
collaboration between the developer, delegates from the 
Dutch inflammatory bowel disease patient organisation 
(CCUVN), nurses, and gastroenterologists working in 
secondary and tertiary referral centres.22 Additionally, we 
deliberately assessed the effects of telemedicine on 
quality of care in a large unselected population of patients 
with all subtypes of inflammatory bowel disease, 
representative of a general inflammatory bowel disease 
population in a specialised care setting,28 thereby 
providing external validity of the results for entire 
populations of patients with inflammatory bowel disease. 
Although this study was done in patients with 
inflammatory bowel disease, the results suggest that 
telemedicine can measure and improve the quality and 
value of health care in patients with other chronic 
relapsing-remitting diseases.
Our results show that telemedicine with myIBDcoach 
was safe, reduced outpatient visits and hospital 
admissions, and improved adherence to medication with 
similar patient-reported quality of care compared with 
standard care. These results were consistent across 
different subtypes of inflammatory bowel disease. This 
telemedicine tool systematically monitors and registers 
disease activity and factors affecting disease, patient-
reported outcome measures, drug side-effects, and 
quality metrics. In an era of health-care cost reduction 
and a rising incidence of inflammatory bowel disease, 
telemedicine systems could be a valuable tool for 
reorganising inflammatory bowel disease care towards 
more personalised and value-based health care.
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